Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 24;6(1):e517.
doi: 10.1097/TXD.0000000000000964. eCollection 2020 Jan.

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters

Florian Terrec  1 , Thomas Jouve  1   2 , Hamza Naciri-Bennani  1 , Pierre-Yves Benhamou  2   3 , Paolo Malvezzi  1   2 , Benedicte Janbon  1 , Diane Giovannini  2   4 , Lionel Rostaing  1   2 , Johan Noble  1   2
Affiliations

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters

Florian Terrec et al. Transplant Direct. .

Abstract

Background: Calcineurin inhibitors (CNIs) and steroids are strongly associated with new-onset diabetes after transplantation, worsening of pre-existing diabetes, and cardiovascular events. We assessed the benefit of conversion from CNI-based to belatacept-based immunosuppression in diabetic kidney-transplant (KT) recipients on glucose control and cardiovascular risk factors.

Methods: In this retrospective, noncontrolled single-study conducted between May 2016 and October 26, 2018, we recruited KT recipients converted from CNIs to belatacept at least 6 months after KT. The primary endpoint was the evolution of hemoglobin A1c (HbA1c) between baseline and after 6 months of treatment. Secondary endpoints included modifications to antidiabetic drugs, other cardiovascular risk factors, and renal function.

Results: One hundred and three KT recipients were included. Of these, 26 (25%) had type 2 diabetes. The patients were either receiving oral antidiabetic drugs (n = 21; 75%) or insulin therapy (n = 14; 54%). Overall HbA1c decreased significantly from 6.2 ± 1 to 5.8 ± 1%, P < 0.001. In diabetic patients, HbA1c decreased from 7.2 ± 1 to 6.5 ± 1%, P = 0.001. HbA1c significantly decreased in the subgroup of patients with new-onset diabetes after transplantation and whether diabetes was controlled at inclusion or not (ie, HA1c ≤7% or >7%). Moreover, no diabetic patient increased the number of oral antidiabetic drugs and the dose of basal insulin was not statistically different from baseline to 6 months (16 international unit at baseline and 16 international unit at 6 mo, P = 1). One patient had to start treatment by insulin pump. During follow-up, the renal function, body mass index, and hemoglobin level of all 103 patients remained stable, 2 patients presented acute cellular rejection, and no patient suffered from graft loss.

Conclusions: A late switch from CNI to belatacept was a valuable therapeutic option for diabetic kidney recipients and substantially improved glycemic parameters.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Study flow chart. CNI, calcineurin inhibitors.
FIGURE 2.
FIGURE 2.
Improvement in HbA1c at 6 mo post–belatacept conversion. Box plots represent HbA1c percentage at inclusion for each patient and at 6 mo. Black lines represent the average. *P < 0.05 as compared with inclusion. HbA1c, hemoglobin A1c.
FIGURE 3.
FIGURE 3.
Evolution of HbA1c at postswitch from CNI to belatacept at 6 mo in the subgroup analyses. Box plots represent the HbA1c percentage at inclusion for each patient and at 6 mo. A, Patients with pre-existing diabetes before kidney transplantation. B, Patients with new-onset diabetes after transplantation. C, Patients with controlled diabetes at inclusion (HbA1c ≤7%). D, Patients with uncontrolled diabetes at inclusion (HbA1c >7%). CNI, calcineurin inhibitors; HbA1c, hemoglobin A1c. *P < 0.05.
See this image and copyright information in PMC

References

    1. Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under FK 506. JAMA. 1990;264:63–67. - PMC - PubMed
    1. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311:699–705. - PubMed
    1. Hošková L, Málek I, Kopkan L, et al. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. Physiol Res. 2017;66:167–180. - PubMed
    1. Rodrigo E, Fernández-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol. 2006;17(12 Suppl 3):S291–S295. - PubMed
    1. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185. - PubMed